Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT00065351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
For each subject the study will consist of two phases: a treatment phase and a follow-up phase. Screening procedures will take place within 28 days of baseline. Treatment Phase: Subjects who qualify for enrollment into the study will receive single-agent CC-5013 in 28-day cycles. Study visits will occur every 4 weeks and hematologic and myeloma paraprotein laboratory assessments will occur every 2 weeks for the first 6 cycles and every 4 weeks thereafter. Follow-Up Phase: All subjects who discontinue the treatment phase for any reason will continue to be followed for survival and post-treatment phase anti-myeloma treatment.
Study identification
- NCT ID
- NCT00065351
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 222 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2003 (Actual)
- Primary completion
- Oct 1, 2006 (Actual)
- Completion
- Mar 1, 2007 (Actual)
- Last update posted
- Nov 12, 2019
2003 – 2007
United States locations
- U.S. sites
- 26
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Verde Hematology Oncology | Glendale | Arizona | 85304 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| Alta Bates Comprehensive Cancer Center | Berkeley | California | 94704 | — |
| Providence St. Joseph Medical Center/Cancer Center | Burbank | California | 91505 | — |
| Wilshire Oncology Medical Group, Inc. | La Verne | California | 91750 | — |
| Institute for Myeloma and Bone | Los Angeles | California | 90067 | — |
| Cancer Care Associates | Redondo Beach | California | 90277 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Northwest Georgia Oncology Centers | Marietta | Georgia | 30060 | — |
| Atlanta Cancer Care-Roswell | Roswell | Georgia | 30076 | — |
| Northwestern University Med Ctr | Chicago | Illinois | 60611-2927 | — |
| Midwest Cancer Research Group | Skokie | Illinois | 60077 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201-1595 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20717 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Massachusetts | Worcester | Massachusetts | 01655 | — |
| Mayo Clinic | Rochester | Minnesota | 55902 | — |
| Nevada Cancer Center | Las Vegas | Nevada | 89109 | — |
| SUNY Health Science Center at Brooklyn | Brooklyn | New York | 11203 | — |
| St. Vincent's Comprehensive Cancer Center | New York | New York | 10011 | — |
| Carolina Hematology-Oncology Associates | Charlotte | North Carolina | 28203 | — |
| Cleveland Clinic Myeloma Program Hematology & Medical Oncology /R35 | Cleveland | Ohio | 44195 | — |
| Western Pennsylvania Cancer Institute | Pittsburgh | Pennsylvania | 15224 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109-1024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00065351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2019 · Synced Oct 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00065351 live on ClinicalTrials.gov.